Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine

Addictive Behaviors

Volumn 31, Issue 11, 2006, Pages 2002-2013

  Ponizovsky, Alexander M ^a   Grinshpoon, Alexander ^a   Margolis, Anatoly ^a   Cohen, Rami ^b   Rosca, Paula ^a  

^a MINISTRY OF HEALTH   (Israel)

^b Association for Public Health   (Israel)

Author keywords

Buprenorphine; Clonidine; Inpatient detoxification; Self efficacy; Side effects; Social support; Well being

Indexed keywords

ANTIEMETIC AGENT; BUPRENORPHINE; CLONIDINE; DIAMORPHINE; DIPYRONE; PHENOBARBITAL; PROMETHAZINE; TRAZODONE;

ADULT; ANALYSIS OF COVARIANCE; ANALYSIS OF VARIANCE; APPETITE DISORDER; ARTICLE; BRADYCARDIA; CHI SQUARE TEST; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEROIN DEPENDENCE; HUMAN; HYPERSALIVATION; HYPERTENSION; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; NERVOUSNESS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SELF CONCEPT; SEMI STRUCTURED INTERVIEW; SIDE EFFECT; SLEEP DISORDER; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TACHYCARDIA; TREATMENT OUTCOME; WEIGHT GAIN; WEIGHT REDUCTION; WELLBEING; XEROSTOMIA;

ADOLESCENT; ADULT; ANALGESICS; ANALGESICS, OPIOID; BUPRENORPHINE; CLONIDINE; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; SELF EFFICACY; SOCIAL SUPPORT; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33749515651     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2006.01.014     Document Type: Article

References (57)

1. Amass L., Bickel W.K., Higgins S.T., and Hughes J.R. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. Journal of Addictive Disorders 13 (1994) 33-45
2. Ben-Ari A., and Gil S. Traditional support systems: Are they sufficient in a culturally diverse academic environment?. British Journal of Social Work 32 (2002) 629-638
3. Brewer D.D., Fleming C.B., Haggerty K.P., and Catalano R.F. Drug use predictors of partner violence in opiate-dependent women. Violence and Victims 13 (1998) 107-115
4. Brooner R.K., King V.L., Kidorf M., Schmidt Jr. C.W., and Bigelow G.E. Psychiatric and substance use comorbidity among treatment-seeking opioid abusers. Archives of General Psychiatry 54 (1997) 71-80
5. Cherubin C.E., and Sapira J.D. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. Annals of Internal Medicine 119 (1993) 1017-1028
6. Cheskin L.J., Fudala P.J., and Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug and Alcohol Dependence 36 (1994) 115-121
7. Cheung S.K., and Sun S.Y. Assessment of optimistic self-beliefs: Further validation of the Chinese version of the General Self-Efficacy Scale. Psychological Reports 85 (1999) 1221-1224
8. Darke S., and Ross J. Polydrug dependence and psychiatric comorbidity among heroin injectors. Drug and Alcohol Dependence 48 (1997) 135-141
9. Digiusto E., Lintzeris N., Breen C., Kimber J., Mattick R.P., Bell J., et al., The NEPOD Research Group. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addictive Behaviors 30 (2005) 443-456
10. DiPaula B.A., Schwartz R., Montoya I.D., Barrett D., and Tang C. Heroin detoxification with buprenorphine on an inpatient psychiatric unit. Journal of Substance Abuse Treatment 23 (2002) 163-169
11. Dohrenwend B.P., Shrout P.E., Egri G., and Mendelsohn F.S. Nonspecific psychological distress and other dimensions of psychopathology. Measures for use in the general population. Archives of General Psychiatry 37 (1980) 1229-1236
12. Duburcq A., Charpak Y., Blin P., and Madec L. Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex). Revue d'Épidémiologie et de Santé Publique 48 (2000) 363-373
13. Fhima A., Henrion R., Lowenstein W., and Charpak Y. Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex). Annales de Médecine Interne 152 Suppl. 3 (2001) IS26-IS36
14. Fingerhood M.I., Thompson M.R., and Jasinski D.R. A comparison of clonidine and buprenorphine in the outpatient treatment of opiate withdrawal. Substance Abuse 22 (2001) 193-199
15. Friedman L.M., Furberg C.D., and DeMets D.L. Fundamentals of clinical trials. 3rd ed. (1998), Springer-Verlag, New York
16. Giacomuzzi S.M., Ertl M., Kemmler G., Riemer Y., and Vigl A. Sublingual buprenorphine and methadone maintenance treatment: A three-year follow-up of quality of life assessment. Scientific World Journal 5 (2005) 452-468
17. Gibson A.E., Doran C.M., Bell J.R., Ryan A., and Lintzeris N. A comparison of buprenorphine treatment in clinic and primary care settings: A randomised trial. Medical Journal of Australia 179 (2003) 38-42
18. Goldberg D.P., and Williams P. A users guide to the general health questionnaire: GHQ (1988), NFER-NELSON, Windsor
19. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug and Alcohol Dependence 21 (1998) 253-259
20. Gowing L., Ali R., and White J. Buprenorphine for the management of opioid withdrawal. Cochrane Database System Review 18 (2004) CD002025
21. Guy W. ECDU assessment manual for psychopharmacology (1976), US Department of Health and Human Services, Rockville, MD
22. Idel M., Melamed S., Merlob P., Yahav J., Hendel T., and Kaplan B. Influence of a merger on nurses' emotional well-being: The importance of self-efficacy and emotional reactivity. Journal of Nursing Management 11 (2003) 59-63
23. Jerusalem M., and Schwarzer R. Selbstwirksamkeit (Self-efficacy). In: Schwarzer R. (Ed). Skalen zur Befindlichkeit und Personlichkeit. Research Report vol. 5 (1986), Freie Universitat, Institut fur Psychologie, Berlin 15-28
24. Jones H.E., Johnson R.E., Bigelow G.E., Silverman K., Mudric T., and Strain E.C. Safety and efficacy of l-tryptophan and behavioral incentives for treatment of cocaine dependence: A randomized clinical trial. American Journal of Addiction 13 (2004) 421-437
25. Kakko J., Svanborg K.D., Kreek M.J., and Heilig M. 1-Year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: A randomised, placebo-controlled trial. Lancet 361 (2003) 662-668
26. Kessler R.C., Price R.H., and Wortman C.B. Social factors in psychopathology: Stress, social support, and coping processes. Annual Review of Psychology 36 (1985) 531-572
27. Koivumaa-Honkanen H.T., Honkanen R., Antikainen R., Hintikka J., and Viinamaki H. Self-reported life satisfaction and treatment factors in patients with schizophrenia, major depression and anxiety disorder. Acta Psychiatrica Scandinavica 99 (1999) 377-384
28. Kosten T.R., and George T.P. The neurobiology of opioid dependence: Implications for treatment. Science and Practice Perspectives 13 (2002) 13-20
29. Liebschutz J.M., Mulvey K.P., and Samet J.H. Victimization among substance-abusing women. Worse health outcomes. Archives of Internal Medicine 157 (1997) 1093-1097
30. Ling W., Amass L., Shoptaw S., Annon J.J., Hillhouse M., Babcock D., et al., Buprenorphine Study Protocol Group. A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: Findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100 (2005) 1090-1100
31. Ling W., and Smith D. Buprenorphine: Blending practice and research. Journal of Substance Abuse Treatment 23 (2002) 87-92
32. Lintzeris N., Bammer G., Rushworth L., Jolley D.J., and Whelan G. Buprenorphine dosing regime for inpatient heroin withdrawal: A symptom-triggered dose titration study. Drug and Alcohol Dependence 70 (2003) 287-294
33. Lintzeris N., Bell J., Bammer G., Jolley D.J., and Rushworth L. A randomized controlled trial of buprenorphine in the management of short-term ambulatory heroin withdrawal. Addiction 97 (2002) 1395-1404
34. Mello N.K., Negus S.S., Lukas S.E., Mendelson J.H., Sholar J.W., and Drieze J. A primate model of polydrug abuse: Cocaine and heroin combinations. Journal of Pharmacology and Experimental Therapeutics 274 (1995) 1325-1337
35. Nigam A.K., Ray R., and Tripathi B.M. Buprenorphine in opiate withdrawal: A comparison with clonidine. Journal of Substance Abuse Treatment 10 (1993) 391-394
36. O'Connor P.G., Carroll K.M., Shi J.M., Schottenfeld R.S., Kosten T.R., and Rounsaville B.J. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals of Internal Medicine 127 (1997) 526-530
37. O'Connor P.G., and Fiellin D.A. Pharmacologic treatment of heroin-dependent patients. Annals of Internal Medicine 133 (2000) 40-54
38. O'Connor P.G., Selwyn P.A., and Schottenfeld R.S. Medical care for injection-drug users with human immunodeficiency virus infection. New England Journal of Medicine 331 (1994) 450-459
39. Oreskovich M.R., Saxon A.J., Ellis M.L., Malte C.A., Reoux J.P., and Knox P.C. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug and Alcohol Dependence 77 (2005) 71-79
40. Pacini M., and Maremmani I. Medical meaning of psychosocial issues of heroin addiction. Heroin Addiction and Related Clinical Problems 7 (2005) 37-48
41. Palmstierna T. Effects of a high-dose fast tapering buprenorphine detoxification program on symptom relief and treatment retention. Journal of Psychoactive Drugs 36 (2004) 273-277
42. Ponizovsky A., Grinshpoon A., Sasson R., and Levav I. Stress in adult students with schizophrenia in a supported education program. Comprehensive Psychiatry 45 (2004) 401-407
43. Rabin S., Kahan E., Zalewsky S., Rabin B., Herz M., Mehudar O., et al. Primary care physicians' attitudes to battered women and feelings of self-competence regarding their care. Israel Medical Association Journal 2 (2000) 753-757
44. Regidor E., Barrio G., de la Fuente L., and Rodriguez C. Non-fatal injuries and the use of psychoactive drugs among young adults in Spain. Drug and Alcohol Dependence 40 (1996) 249-259
45. Rosenberger W.F., and Lachin J.M. Randomization in clinical trials: Theory and practice (2002), Wiley, New York
46. Ritsner M., Modai I., Endicott J., Rivkin O., Nechamkin Y., Barak P., et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. Journal of Clinical Psychiatry 61 (2000) 880-889
47. Ritsner M., Ponizovsky A., Endicott J., Nechamkin Y., Rauchverger B., Silver H., et al. The impact of adverse events of antipsychotics on life satisfaction of schizophrenia patients: A naturalistic study. European Neuropsychopharmacology 12 (2002) 31-38
48. Shaham Y., Erb S., and Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: A review. Brain Research Reviews 33 (2000) 13-33
49. Skaret E., Kvale G., and Raadal M. General self-efficacy, dental anxiety and multiple fears among 20-year-olds in Norway. Scandinavian Journal of Psychology 44 (2003) 331-337
50. Sporer K.A. Acute heroin overdose. Annals of Internal Medicine 130 (1999) 584-590
51. Stein M.D. Medical complications of intravenous drug use. Journal of General Internal Medicine 5 (1990) 249-257
52. Tollefson G.D., and Andersen S.W. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. Journal of Clinical Psychiatry 60 Suppl 5 (1999) 23-29
53. Turner R.J., and Marino F. Social support and social structure: A descriptive epidemiology. Journal of Health and Social Behavior 35 (1994) 193-212
54. Wethington E., and Kessler R.C. Perceived support, received support, and adjustment to stressful life events. Journal of Health and Social Behavior 27 (1986) 78-89
55. Wyshak G., and Modest G.A. Violence, mental health, and substance abuse in patients who are seen in primary care settings. Archives of Family Medicine 5 (1996) 441-447
56. Ziedonis D., and Brady K. Dual diagnosis in primary care. Detecting and treating both the addiction and mental illness. Medical Clinics of North America 81 (1997) 1017-1036
57. Zimet G.D., Dahlem N.W., Zimet S.G., and Farley G.K. The multidimensional scale of perceived social support. Journal of Personality Assessment 52 (1988) 30-41